Navigation Links
Boceprevir: Indication of added benefit for specific patients
Date:12/9/2011

The active ingredient boceprevir has been available since the middle of 2011 as a treatment for chronic hepatitis C of genotype 1. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined to establish whether boceprevir offers added benefit in comparison with the previous standard therapy. According to this assessment, the dossier submitted by the pharmaceutical company provides indications of added benefit for patients who have not yet developed liver cirrhosis. However, the extent of this added benefit cannot be classified.

The pharmaceutical company provided no data - or inadequate data - for two other indications - patients with liver cirrhosis and patients for whom prior treatment was totally ineffective (zero response to prior interferon-based therapy) - and therefore added benefit for these patients is not proven.

An addition to previous standard drug therapy

Hepatitis C viruses attack the liver and can trigger inflammation there. If this becomes chronic, cirrhosis can develop and liver function progressively deteriorates. Moreover, the risk of liver cancer (hepatocellular carcinoma, HCC) increases. Boceprevir (trade name Victrelis, manufacturer MSD Sharp & Dohme) inhibits the reproduction of hepatitis C viruses. Experts assume that if no viruses are detectable in the blood over a sustained period after treatment (sustained virological response, SVR), the risk of secondary disease is reduced.

Boceprevir is administered in addition to the active ingredients peginterferon alfa and ribavirin, which are already on the market. In accordance with the approval status, different patient groups are treated for different periods, as was allowed for in the assessment. The dual combination of peginterferon alfa and ribavirin has been the standard therapy and this was compared with boceprevir given in a triple combination with the former two drugs.

Reduction in secondary diseases: extent cannot be classified.

For the two indications of pretreated (treatment-experienced) and non-pretreated (treatment-naive) patients without cirrhosis, data from one approval study each (SPRINT-2 and RESPOND-2) were available. With the available studies, it is not possible to assess directly whether the new active ingredient influences secondary diseases, such as the development of liver cancer. This is partly because the studies have not lasted long enough for these patient-relevant outcomes to be recorded.

With respect to SVR, there was a clear advantage for boceprevir, both for pretreated patients and for non-pretreated patients without liver cirrhosis. However, SVR is not itself a patient-relevant outcome and cannot be equated with "cure", and there are no studies in which SVR is validated as a surrogate outcome in accordance with the usual criteria employed by IQWiG. Nevertheless, the Institute accepts SVR in the context of the assessment as a surrogate for the reduced incidence of liver cancer. This is because it is currently accepted that patients with no detectable hepatitis C virus in the blood are at lower risk of liver cancer. However, it is unclear how many cases of liver cancer can in fact be prevented by boceprevir.

For the outcome "secondary diseases", IQWiG recognizes an "indication" of a benefit for boceprevir. The requirements for a "proof" are not fulfilled, one reason being that the data are only derived from a single study each, with a comparatively small number of patients. Moreover, the scientific data do not permit a conclusive assessment of the number of patients in whom liver cancer is actually prevented. It is therefore unclear whether the added benefit is "minor", "considerable" or "major". For such a case, the corresponding legal ordinance specifies the assessment category of "unquantifiable".

Indication of greater harm for patients without prior treatment

The indication of greater benefit is in contrast to the indication of greater harm, but only in previously untreated patients. In these patients, boceprevir more often led to anaemia, although this was rarely serious. IQWiG classified the extent of this greater harm as "considerable". In contrast, in patients with prior treatment, anaemia was no more frequent than with standard treatment.

Effect on mortality unclear

IQWiG established that the approval studies contained inadequate data on quality of life for patients with or without prior treatment. There were no statistically significant differences in mortality between the treatment groups. It thus remains unclear if and how boceprevir influences mortality.


'/>"/>
Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Prasugrel: Indications of an additional benefit for some patients, but also of greater harm
2. Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
3. Indications of Alzheimers disease may be evident decades before first signs of cognitive impairment
4. Early indications of Parkinsons disease revealed in dream sleep
5. Calorie count plus points based on added sugars, sodium, and saturated and trans fats recommended as new front-of-package nutrition labeling system
6. Ticagrelor: Considerable added benefit for specific patients
7. Hospitals encouraged to consider value-added service of hospital-based radiology groups
8. Pelvic Mesh for Incontinence May Carry Added Risk for Women: FDA
9. Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
10. Newer Versions of the Pill Pose No Added Risk to Gallbladder
11. More Added Sugars, More Pounds?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... More than a third of American adults are considered obese, says the ... increased attention in recent years, as an article published May 18th on ... people are familiar with the basic requirements of maintaining a healthy diet and exercise ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of ... demand for a sustainable product to aid in the rehabilitation process has steadily increased. ... recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has now received ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... ... world, this installment is bolstered by inspiring human interest stories, courtesy of leaders ... developing trends and tech within the industry, from leading advocates and associations—namely Jones ...
(Date:5/26/2016)... , ... May 26, 2016 , ... There are many ... Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the ... percent say grilling is their favorite way to cook a hot dog, far outpacing ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its Connor Cares ... the Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s ... surfaces in all forms and levels of the game, Connor Sports has committed to ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 Hutchison ... company focused on the highly lucrative global oncology ... pipeline of potential first-in-class or best-in-class tyrosine kinase ... development with strategic partners. HCM,s profitable Chinese healthcare ... market. We expect progress of the mid-to-late-stage pipeline ...
(Date:5/27/2016)... -- Amarantus BioScience Holdings, Inc. (OTCQX: ... Medicine, Neurology and Orphan Diseases, today announced that President & CEO ... investor conferences: SeeThru Equity MicroCap Conference   ... York City , NY When: Tuesday, May 31 ...   Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... , May 26, 2016 According to ... Waste Management Market - U.S. Industry Analysis, Size, Share, Growth, ... market in the U.S. was valued at US$ 5.89 Bn ... of 3.4% from 2015 to 2023 to reach US$ 7.99 ... of current and emerging needle free drug delivery devices and ...
Breaking Medicine Technology: